Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: A growing number of studies have investigated the efficacy of novel, adjunctive pharmacotherapies for treatment of cognitive deficits in schizophrenia with conflicting results. Aims: To investigate the comparative efficacy of these agents on cognition and symptoms in schizophrenia, and to identify promising cognitive domains and candidate medications that can be incorporated in treatment trials combined with cognitive remediation to maximise treatment effects. Method: A total of 26 double-blind, placebo-controlled studies investigating medications targeted at cholinergic, glutamatergic or serotonergic receptor classes and with participants with schizophrenia or schizoaffective disorder were identified. Results: Medications targeted at the cholinergic receptor class produced marginal improvements in verbal learning and memory (d= 0.23,P= 0.06), and donepezil, a specific type of cholinergic agonist, produced a moderate effect (d= 0.58) on spatial learning and memory. Cholinergic and glutamatergic agents produced moderate effect-size improvements on negative symptoms (d= 0.54 and d= 0.62 respectively), and small effect-size improvements on general symptoms (d= 0.46 and d= 0.41 respectively). Serotonergic agents produced small effect-size improvements in positive symptoms (d= 0.33). Conclusions: Cholinergic medications produced marginal improvement in verbal learning and memory and moderate improvements on spatial learning and memory, although there was no evidence to support the use of glutamatergic or serotonergic medications as a stand-alone treatment for improving cognitive function. Cholinergic and glutamatergic agents improved negative and general symptoms, whereas serotenergic medications improved positive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distribution Theory for Glass's Estimator of Effect Size and Related Estimators
Hedges, L. V. (1981) · Journal of Educational Statistics · doi:10.2307/1164588 · Cited by 5,695
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Fixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
A Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
Self-citationKeefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Cited by
GERAD1 Consortium, Pardiñas, A. F., CRESTAR Consortium, Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S. E., Bishop, S., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0059-2 · Cited by 1,552
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses
Carvalho, A. F., Bortolato, B., Miskowiak, K., Vieta, E., & Köhler, C. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s76700 · Cited by 306
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Correll, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Metadata
- Authors
- Choi, K.-H., Wykes, T., & Kurtz, M. M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2013-09
- Volume
- 203
- Issue
- 3
- Pages
- 172-178
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2120754512
- Cited by
- 100
- References
- 14
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. https://app.cochat.ai/papers/10.1192/bjp.bp.111.107359
- The paper
- Choi, K.-H., Wykes, T., & Kurtz, M. M. (2013). Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.111.107359
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.